Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study

<div>Follow-up of patients who discontinued anti-PD-1, University Hospital of Bordeaux, 2019. Of the 65 patients included, 38% (<i>n</i> = 25) discontinued treatment for CR, 18% (<i>n</i> = 12) for PR or SD, and 43% (<i>n</i> = 28) because of AEs.</div>

Journal of Oncology

fig2

Figure 2

Figure 2: Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study 

Figure 2 | Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study 